Prostate Cancer Trial, Recruiting NCT06101290 Sponsor: University of California, Davis Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06101290
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been confirmed by lab testing to have one of three types of cancer: prostate cancer (Cohort A), urothelial carcinoma — a cancer of the bladder or urinary tract (Cohort B), or renal cell carcinoma — a type of kidney cancer (Cohort C).
  • People who are willing and able to sign and date a consent form agreeing to take part in the study.
  • People who are willing to follow all study procedures and are available for the full duration of the study.
  • People who are 18 years of age or older at the time of giving consent.
  • People who are currently receiving a systemic (whole-body) cancer treatment and whose doctors plan for them to continue that same treatment, with no more than a 30-day pause to allow for a targeted local treatment.
  • People who have already received at least one round of systemic treatment for cancer that has spread to other parts of the body, and whose most recent treatment has been working well for at least 3 months before new or growing spots appeared — meaning their doctor considers most of the cancer to be stable and not yet requiring a change in treatment.
  • People who have 5 or fewer new or growing cancer spots in the body.
  • People whose new or growing cancer spots can all be safely treated with targeted local therapies, as determined by the treating radiation oncologist and/or interventional radiologist.

Who may not be able to join:

  • People whose other health conditions make targeted local treatments unsafe for them.
  • People who have previously experienced side effects from prior treatments that would prevent or limit the safe use of targeted local treatments.
  • People who have cancer spots in the brain that are currently growing.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mamta Parikh, MD, MS, University of California, Davis

Phone: 916-382-6970

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 December 2023
Est. completion
15 December 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with controlled disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov